Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy

被引：112

作者：

Cavo, M ^{[1
]}

Zamagni, E ^{[1
]}

Cellini, C ^{[1
]}

Tosi, P ^{[1
]}

Cangini, D ^{[1
]}

Cini, M ^{[1
]}

Valdrè, L ^{[1
]}

Palareti, G ^{[1
]}

Masini, L ^{[1
]}

Tura, S ^{[1
]}

Baccarani, M ^{[1
]}

机构：

[1] Inst Hematol & Med Oncol Seragnoli, I-40138 Bologna, Italy

来源：

BLOOD | 2002年 / 100卷 / 06期

关键词：

D O I：

10.1182/blood-2002-06-1674

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：2272 / 2273

页数：2

共 8 条

[1] Thalidomide in the management of multiple myeloma [J].

Barlogie, B ;

Zangari, M ;

Spencer, T ;

Fassas, A ;

Anaissie, E ;

Badros, A ;

Cromer, J ;

Tricot, G .

SEMINARS IN HEMATOLOGY, 2001, 38 (03) :250-259

[2] Thalidomide and dexamethasone combination for refractory multiple myeloma [J].

Dimopoulos, MA ;

Zervas, K ;

Kouvatseas, G ;

Galani, E ;

Grigoraki, V ;

Kiamouris, C ;

Vervessou, E ;

Samantas, E ;

Papadimitriou, C ;

Economou, O ;

Gika, D ;

Panayiotidis, P ;

Christakis, I ;

Anagnostopoulos, N .

ANNALS OF ONCOLOGY, 2001, 12 (07) :991-995

[3] Deep venous thrombosis and thalidomide therapy for multiple myeloma. [J].

Osman, K ;

Comenzo, R ;

Rajkumar, SV .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (25) :1951-1952

[4]

Palumbo A, 2001, HAEMATOLOGICA, V86, P399

[5] Antitumor activity of thalidomide in refractory multiple myeloma. [J].

Singhal, S ;

Mehta, J ;

Desikan, R ;

Ayers, D ;

Roberson, P ;

Eddlemon, P ;

Munshi, N ;

Anaissie, E ;

Wilson, C ;

Dhodapkar, M ;

Zeldis, J ;

Barlogie, B ;

Siegel, D ;

Crowley, J .

NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (21) :1565-1571

[6]

Tosi P, 2002, HAEMATOLOGICA, V87, P408

[7] Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy [J].

Zangari, M ;

Siegel, E ;

Barlogie, B ;

Anaissie, E ;

Saghafifar, F ;

Fassas, A ;

Morris, C ;

Fink, L ;

Tricot, G .

BLOOD, 2002, 100 (04) :1168-1171

[8] Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy [J].

Zangari, M ;

Anaissie, E ;

Barlogie, B ;

Badros, A ;

Desikan, R ;

Gopal, AV ;

Morris, C ;

Toor, A ;

Siegel, E ;

Fink, L ;

Tricot, G .

BLOOD, 2001, 98 (05) :1614-1615

← 1 →